PALI

Announcements

Nothing here yet

Daily updates

• Palisade Bio will present Phase 1b clinical and translational data for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease at UEG Week 2026 on October 17–20.Sep 29, 2026

FDA designations

Nothing here yet

News

• Palisade Bio presents new clinical, pharmacokinetic, pharmacodynamic and mechanistic data supporting Phase 2 development of PALI-2108 for ulcerative colitis and Crohn’s disease at ACG 2026Oct 12, 2026
• Palisade Bio expands its global Phase 2b ASCENTRA-UC program following Health Canada CTA clearanceSep 23, 2026
• Palisade Bio receives FDA IND clearance for PALI-2108 in Crohn's disease, expanding its Phase 2 IBD development programSep 22, 2026
• Palisade Bio received FDA clearance for its IND application for PALI-2108 and planned a global Phase 2 ulcerative colitis trialJun 29, 2026
• Palisade Bio reported additional Phase 1a/b data showing colon-targeted exposure and sustained IC90 coverage supporting once-daily dosing in ulcerative colitisMay 5, 2026